01—Abstract
Summary
Summary of the 10-K filed February 4, 2013. Cited figures are marked; the original filing is the authoritative source.
Intuitive Surgical, Inc. (ISRG) in its 2013 10-K filing for the year ended December 30, 2012, reported robust revenue growth of 24% to $2.18 billiona, driven by a 25% increase in da Vinci procedures performed globally, reaching approximately 450,000.
This growth was fueled by strong performance in U.S. gynecologic and general surgery procedures, as well as international prostatectomies, partially offset by a decline in U.S. prostatectomies due to changes in PSA screening recommendations and disease management. The company continues to see a favorable trend in recurring revenue from instruments, accessories, and service, which now represents 57%b of total revenue. This recurring revenue stream is a key indicator of customer stickiness and ongoing system utilization.
ISRG also demonstrated strong operational execution with a 26% increase in operating income and a healthy cash flow from operations, ending the year with nearly $3 billionc in cash, cash equivalents, and investments. The company continues to invest in research and development to expand its product portfolio, including new instruments and imaging technologies.
02—Key points
Key Highlights
- Total revenue increased by 24% to $2.18 billion in 2012.
- Global da Vinci procedures increased by 25% to approximately 450,000 in 2012.
- Recurring revenue (instruments, accessories, and service) grew 27% and represented 57% of total revenue.
- Operating income grew 26% to $878.1 million.
- The company sold 620 da Vinci Surgical Systems in 2012, an increase from 534 in 2011.
- Ended the year with $2.92 billion in cash, cash equivalents, and investments.
- U.S. Prostatectomy (dVP) procedures saw a 15% decline, attributed to changes in PSA screening and non-surgical disease management.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2012, Intuitive Surgical kept $0.30.
- Revenue$2.18B100.0%
- Cost of revenue−$608.5M27.9%
- Gross profit$1.57B72.1%
- Operating costs−$692.2M31.8%
- Operating income$878.1M40.3%
- Interest, other & tax−$221.5M10.2%
- Net income$656.6M30.1%
Where FY2012 revenue went
$2.18B- Net income: $656.6M, 30% of revenue
- Cost of revenue: $608.5M, 28% of revenue
- SG&A: $522.2M, 24% of revenue
- R&D: $170.0M, 7.8% of revenue
- Interest, other & tax: $221.5M, 10% of revenue
Kept 30% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2012filed February 4, 2013Financial Statements
FY2012 against FY2011
| Line item | FY2012FY2011 | Change |
|---|---|---|
| Revenue | $2.18B$1.76B | +24.0% |
| Cost of Revenue | $608.50M$483.50M | +25.9% |
| Gross Profit | $1.57B$1.27B | +23.3% |
| R&D Expenses | $170.00M$140.20M | +21.3% |
| SG&A Expenses | $522.20M$438.80M | +19.0% |
| Operating Expenses | $692.20M$579.00M | +19.6% |
| Operating Income | $878.10M$694.80M | +26.4% |
| Net Income | $656.60M$495.10M | +32.6% |
| EPS (Basic) | $1.83$1.40 | +30.6% |
| EPS (Diluted) | $1.78$1.37 | +29.7% |
| Shares Outstanding (Basic) | 358.20M352.80M | +1.5% |
| Shares Outstanding (Diluted) | 369.90M361.80M | +2.2% |
05—Questions
Frequently Asked Questions
What is the primary driver of Intuitive Surgical's revenue growth?
The primary driver of revenue growth is the increasing adoption of da Vinci Surgical Systems, leading to a higher volume of da Vinci procedures performed globally. This is further supported by recurring revenue from instruments, accessories, and service contracts.
What is the company's strategy for future growth?
Intuitive Surgical's strategy focuses on increasing patient value by performing more procedures with less invasiveness and greater efficacy. This includes converting open procedures to da Vinci surgery, facilitating difficult minimally invasive surgeries, and continuously innovating new products and improving existing ones to expand clinical applications.
What are the key risks or challenges facing Intuitive Surgical?
Key risks include achieving continued market acceptance for da Vinci surgery, economic conditions impacting capital spending by hospitals, competition from established and emerging players, regulatory hurdles for new product introductions, and the potential for adverse results in legal proceedings. A significant challenge noted is the decline in U.S. prostatectomy procedures due to changes in medical guidelines and treatment preferences.
How does the company manage its international operations?
The company sells its products through a direct sales organization in key markets like the U.S. and parts of Europe, and through distributors in other regions. International revenue accounted for 21% of total revenue in 2012, with efforts focused on obtaining regulatory approvals and reimbursement for procedures in markets like Japan.
06—Continue